Reshape Lifesciences Stock Performance
| RSLS Stock | USD 5.73 0.10 1.78% |
The company holds a Beta of -0.14, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning ReShape Lifesciences are expected to decrease at a much lower rate. During the bear market, ReShape Lifesciences is likely to outperform the market. At this point, ReShape Lifesciences has a negative expected return of -0.42%. Please make sure to check ReShape Lifesciences' treynor ratio and rate of daily change , to decide if ReShape Lifesciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ReShape Lifesciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 3.3 | Five Day Return 7.03 | Year To Date Return (61.60) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:58 | Dividend Date 2019-07-25 | Last Split Date 2024-09-23 |
1 | ReShape Lifesciences announces 1-for-58 reverse stock split | 09/19/2024 |
2 | Acquisition by Thomas Stankovich of 1000 shares of ReShape Lifesciences at 0.9 subject to Rule 16b-3 | 09/20/2024 |
3 | Trend Tracker for - Stock Traders Daily | 09/26/2024 |
4 | Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.25 subject to Rule 16b-3 | 10/11/2024 |
5 | Reshape Lifesciences Inc Q3 2024 Earnings Call Highlights Revenue Growth and Strategic ... | 11/15/2024 |
6 | Disposition of 2699 shares by Bandy Barton P. of ReShape Lifesciences at 0.96 subject to Rule 16b-3 | 11/20/2024 |
7 | Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.17 subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 4 M |
ReShape |
ReShape Lifesciences Relative Risk vs. Return Landscape
If you would invest 873.00 in ReShape Lifesciences on September 1, 2024 and sell it today you would lose (300.00) from holding ReShape Lifesciences or give up 34.36% of portfolio value over 90 days. ReShape Lifesciences is currently does not generate positive expected returns and assumes 6.9198% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than ReShape, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ReShape Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ReShape Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ReShape Lifesciences, and traders can use it to determine the average amount a ReShape Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0603
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RSLS |
Estimated Market Risk
| 6.92 actual daily | 61 61% of assets are less volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ReShape Lifesciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ReShape Lifesciences by adding ReShape Lifesciences to a well-diversified portfolio.
ReShape Lifesciences Fundamentals Growth
ReShape Stock prices reflect investors' perceptions of the future prospects and financial health of ReShape Lifesciences, and ReShape Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ReShape Stock performance.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.05) % | ||||
| Current Valuation | 3.55 M | ||||
| Shares Outstanding | 712.68 K | ||||
| Price To Book | 2.76 X | ||||
| Price To Sales | 0.53 X | ||||
| Revenue | 8.68 M | ||||
| Gross Profit | 6.8 M | ||||
| EBITDA | (14.48 M) | ||||
| Net Income | (11.39 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 16.48 X | ||||
| Cash Flow From Operations | (16.96 M) | ||||
| Earnings Per Share | 76.20 X | ||||
| Market Capitalization | 3.64 M | ||||
| Total Asset | 10.66 M | ||||
| Retained Earnings | (635.57 M) | ||||
| Working Capital | 6.52 M | ||||
About ReShape Lifesciences Performance
Assessing ReShape Lifesciences' fundamental ratios provides investors with valuable insights into ReShape Lifesciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ReShape Lifesciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 436.25 | 414.44 | |
| Return On Tangible Assets | (1.07) | (1.12) | |
| Return On Capital Employed | (2.13) | (2.23) | |
| Return On Assets | (1.07) | (1.12) | |
| Return On Equity | (1.71) | (1.79) |
Things to note about ReShape Lifesciences performance evaluation
Checking the ongoing alerts about ReShape Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ReShape Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ReShape Lifesciences generated a negative expected return over the last 90 days | |
| ReShape Lifesciences has high historical volatility and very poor performance | |
| ReShape Lifesciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.68 M. Net Loss for the year was (11.39 M) with profit before overhead, payroll, taxes, and interest of 6.8 M. | |
| ReShape Lifesciences currently holds about 11.49 M in cash with (16.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| ReShape Lifesciences has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.17 subject to Rule 16b-3 |
- Analyzing ReShape Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ReShape Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining ReShape Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ReShape Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ReShape Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ReShape Lifesciences' stock. These opinions can provide insight into ReShape Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.